News | August 10, 2022
Natco Pharma consolidated Q1FY23 PAT jumps to Rs. 320.4 Cr
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
The product will be launched by NATCO's commercial partner Viatris.
This lawsuit has been filed in the Pennsylvania Federal Court. NATCO and its marketing partner Mylan
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
The cash consideration for the acquisition is US$ 18 million.
It is used for the treatment of advanced colorectal and gastric cancer
Natco Pharma has reported consolidated financial results for the period ended September 30, 2021
Subscribe To Our Newsletter & Stay Updated
